Foresee Pharmaceuticals Co., Ltd. (Foresee) is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (TPEx: 6576). Our mission is to provide patients with more medical options in comfort, compliance, convenience, and cure. We strive to improve patients' quality of life and provide cure through innovative research. Foresee's R&D efforts are focused on two key areas, namely its unique Stabilized Injectable Formulation - Long-Acting Injectable (SIF-LAI) technologies with derived drug products targeting specialty markets, and secondly, its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs.

Foresee has two core technologies:

• Long-Acting Injectable (LAI) Technologies：Stabilized Injectable Formulation (SIF), a sustained-release drug delivery platform
  

  Our proprietary SIF-LAI drug delivery technologies, enables us to develop differentiated, ready-to-use long-acting injectable products through 505(b)(2) or 505(b)(1) regulatory pathway. To date, the SIF delivery system has demonstrated its applications to small molecules and peptides, including in Foresee’s approved and launched product CAMCEVI®. Products currently under development are FP-014 (Triptorelin, for prostate cancer), FP-016(neurology / psychiatry), FP-017 (neurology / psychiatry), and other products at earlier stage and others not currently core to our portfolio strategy.

• Rational Drug Design：First-in-class new drug (New Chemical Entity, NCE) development
  

  Our rationally-designed first/best-in-class, oral small molecule candidates (NCEs) are targeting complex, hard to drug targets. Products currently under development are
  ◆ MMP-12 inhibitors: FP-025 ( aderamastat, for cardiac sarcoidosis) and its follow-on compound FP-020 (linvemastat, asthma / inflammatory bowel disease / chronic obstructive pulmonary disease) and new series of MMP-12 inhibitors (interstitial lung diseases / neurology)
  ◆ ALDH2 activators: FP-045 (mirivadelgat, for Fanconi anemia / pulmonary hypertension associated with interstitial lung disease) and its follow-on compound (for CVRM / neurology)

Forsee's management team consists of seasoned pharmaceutical professionals with many years of industry experience in pharmaceutical R&D and management. To rapidly advance its pipeline products, Foresee has also teamed up with a network of advisors and consultants in the area of medical, legal, regulatory, business development, and commercial, among others. These advisors and consultants are industry veterans with significant experience and expertise in their respective fields and many are key opinion leaders (KOLs). Foresee has also established long-term partnerships with commercial contract development manufacturers (CDMOs) of drug substance and drug product, and other supply chain vendors to manage clinical trial materials and commercial supplies. In addition, Foresee has also partnered with established global and regional pharmaceutical companies to commercialize and launch their development-stage and approved products across the globe. These partnerships provide the resources and flexibility required to rapidly deliver our medicines to patients across the globe thus improving their standard of care.